Related content

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

By Cohen C.   Nieto-Cisneros L.   Zala C.   Fessel W. J.   Gonzalez-Garcia J.   Gladysz A.   McGovern R.   Adler E.   McLaren C.    

Current Medical Research and Opinion, Vol. 21, Iss. 10, 2005-10 ,pp. : 1683-1692

Informa Healthcare

Access to resources Recommend Favorite

Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: Prevalence and predictors

By Giambenedetto Simona Di   Bacarelli Alessanra   Pinnetti Carmen   Colafigli Manuela   Prosperi Mattia   Gatti Giorgio   Cauda Roberto   De Luca Andrea  

Scandinavian Journal of Infectious Diseases, Vol. 39, Iss. 9, 2007-01 ,pp. : 813-818

Informa Healthcare

Access to resources Recommend Favorite

Effects of NO‐Hybridization on the Immunomodulatory Properties of the HIV Protease Inhibitors Lopinavir and Ritonavir

By  

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 117, Iss. 5, 2015-11 ,pp. : 306-315

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen

By Yilmaz Aylin   Ståhle Lars   Hagberg Lars   Svennerholm Bo   Fuchs Dietmar   Gisslén Magnus  

Scandinavian Journal of Infectious Diseases, Vol. 36, Iss. 11-12, 2004-12 ,pp. : 823-828

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II‐III)

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 25, Iss. 2, 2018-02 ,pp. : 118-125

John Wiley & Sons Inc

Access to resources Recommend Favorite